OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia	454
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	269
Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID‐19: A Nationwide Cohort Study in South Korea	214
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients	183
Quantitative Systems Pharmacology‐Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease	169
Collaborative Real‐World Evidence Among Regulators: Lessons and Perspectives	117
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	106
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	105
Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers	100
Optimal Trough Concentration of Tacrolimus in Pediatric Patients With Primary Nephrotic Syndrome	96
	84
Cerebral Ischemia Protection After Aneurysmal Subarachnoid Hemorrhage: CSF Nimodipine Levels After Intravenous Versus Oral Nimodipine Administration	82
Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women	81
A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information	80
A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real‐World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluat	77
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers	68
Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy	62
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported	60
The Impact of the CYP2D6 “Enhancer” Single Nucleotide Polymorphism on CYP2D6 Activity	58
Artificial Neural Network vs. Pharmacometric Model for Population Prediction of Plasma Concentration in Real‐World Data: A Case Study on Valproic Acid	56
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice	56
Patient‐Centric Clinical Pharmacology: A Journey from Discovery to Recovery	55
	52
The European List of Key Medicines for Medical Education: A Modified Delphi Study	51
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	51

Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	50
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV	49
Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men	46
Trends in Clinical Pharmacology and Therapeutics	46
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	45
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies	45
Neurodegenerative Diseases: The Value of Early Predictive End Points	44
Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants	44
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review	43
Advancing Innovations in Biosimilars	42
Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project	42
Landscape Analysis of the Application of Artificial Intelligence and Machine Learning in Regulatory Submissions for Drug Development From 2016 to 2021	41
Features of Inflammatory Heart Reactions Following mRNA COVID‐19 Vaccination at a Global Level	40
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	39
On the Manufacturers of Biosimilars in Asia	39